N₂-mesitylpyridine-2,3-diamine | 444325-84-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N₂-mesitylpyridine-2,3-diamine
• 英文别名: N²-mesitylpyridine-2,3-diamine；2-N-(2,4,6-trimethylphenyl)pyridine-2,3-diamine
• CAS: 444325-84-2
• 化学式: C₁₄H₁₇N₃
• mdl: MFCD11562418
• 分子量: 227.309
• InChiKey: JPUBFIZUCRYZFH-UHFFFAOYSA-N

物化性质

• 沸点：
  378.2±42.0 °C(Predicted)
• 密度：
  1.137±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.214
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N₂-mesitylpyridine-2,3-diamine 在 乙酸酐 、 碳酸氢钠 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 36.0h， 生成 Ethyl 4-methyl-7-(2,4,6-trimethylphenyl)-2,5,7,9-tetrazatricyclo[6.4.0.02,6]dodeca-1(8),3,5,9,11-pentaene-3-carboxylate
  参考文献：
  名称：

  口服活性促肾上腺皮质激素释放因子1受体拮抗剂，来自8-芳基-1,3a，7,8-四氮杂-环戊[a]茚。

  摘要：

  8-芳基-1,3a，7,8-四氮杂-环戊[a]茚代表一系列新的高亲和性促肾上腺皮质激素释放因子-1受体（CRF1R）拮抗剂。在此，我们报道了在小鼠冠层模型中三环核心周围的合成和SAR，以及口服剂量的示例性化合物9d（K（i）= 8.0 nM）的抗焦虑活性。

  DOI：

  10.1016/j.bmcl.2007.01.008
• 作为产物：
  描述：

  2,4,6-三甲基苯胺 在 potassium fluoride 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0~120.0 ℃ 、350.01 kPa 条件下， 反应 24.0h， 生成 N₂-mesitylpyridine-2,3-diamine
  参考文献：
  名称：

  铂（II）咪唑并吡啶配合物的骨架

  摘要：

  报道了具有独特光物理性质的环金属化C ^ C *铂（II）配合物的合成和表征，聚集诱导了量子产率的提高，同时降低了磷光寿命。另外，通过激发波长的变化引起发射颜色的变化。这些配合物的聚集行为受取代基的空间需求控制。这些配合物的光物理性质通过发射激发矩阵分析（EEM）进行研究。单体配合物是出色的室温磷光蓝色发射体，最大发射峰低于470 nm，量子产率高达93％。

  DOI：

  10.1002/chem.201703908

文献信息

• Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate
  作者：Yu'ning Song、Xiaoqian Lin、Dongwei Kang、Xiao Li、Peng Zhan、Xinyong Liu、Qingzhu Zhang

  DOI：10.1016/j.ejmech.2014.05.063

  日期：2014.7

  prognosis. Thus, inhibiting CDC25 activity in cancer treatment appears a good therapeutic strategy. In this article, refinement of the initial hit XDW-1 by synthesis and screening of a focused compound library led to the identification of a novel set of imidazopyridine derivatives as potent CDC25 inhibitors. Among them, the most potent molecule was CHEQ-2, which could efficiently inhibit the activities

  细胞分裂周期（CDC）25蛋白是通过与CDK /细胞周期蛋白复合物相互作用调节细胞周期过渡和增殖的关键磷酸酶。CDC25蛋白的过表达在癌症中经常被观察到，并且与侵略性，高级别肿瘤和不良预后有关。因此，在癌症治疗中抑制CDC25活性似乎是一种很好的治疗策略。在本文中，通过合成和筛选聚焦的化合物文库对最初命中的XDW-1进行了优化，从而鉴定出一套新的咪唑并吡啶衍生物作为有效的CDC25抑制剂。其中最有效的分子是CHEQ-2，它可以在体外有效抑制CDC25A / B酶的活性以及各种不同类型癌细胞的增殖。分析。此外，CHEQ-2触发了MCF-7，HepG2和HT-29细胞系的S期细胞周期停滞，并伴有ROS的产生，线粒体功能障碍和凋亡。此外，口服CHEQ-2（10 mg / kg）可显着抑制裸鼠体内异种移植的人肝肿瘤的生长，同时显示出极低的毒性（LD 50  > 2000 mg / kg）。这些发现
• 一种咪唑并吡啶巯乙酸类衍生物及其制备方 法与应用
  申请人：山东大学

  公开号：CN106083847B

  公开（公告）日：2018-10-30

  本发明涉及一种咪唑并吡啶巯乙酸类衍生物及其制备方法和应用。所述化合物具有式I、II、III所示的结构。本发明还涉及含有式I、II、III结构化合物的制备方法以及药物组合物。本发明还提供上述化合物在制备抗痛风的药物中的应用。
• Imidazolyl derivatives as corticotropin releasing factor inhibitors
  申请人：——

  公开号：US20020183375A1

  公开（公告）日：2002-12-05

  The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1 useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

  本发明涉及一种新型杂环拮抗剂，其化学式为(I)，以及包含所述拮抗剂的药物组合物，用于治疗抑郁症、焦虑症、情感障碍、进食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状和其他可以通过拮抗CRF-1受体来治疗的疾病。
• Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability
  作者：Tong Zhao、Qing Meng、Zhuosen Sun、Yanyu Chen、Wei Ai、Zean Zhao、Dongwei Kang、Yue Dong、Ruipeng Liang、Ting Wu、Jianxin Pang、Xinyong Liu、Peng Zhan

  DOI：10.1021/acs.jmedchem.0c00223

  日期：2020.10.8

  Lesinurad, a human urate transporter 1 (URAT1) inhibitor approved as a medication for the treatment of hyperuricemia associated with gout in 2015, can cause liver and renal toxicity. Here, we modified all three structural components of lesinurad by applying scaffold hopping, bioisosterism, and substituent-decorating strategies. In a mouse model of acute hyperuricemia, 21 of the synthesized compounds showed increased serum uric acid (SUA)-reducing activity; SUA was about 4-fold lower in animals treated with 44, 54, and 83 compared with lesinurad or benzbromarone. In the URAT1 inhibition assay, 44 was over 8-fold more potent than lesinurad (IC50: 1.57 mu M vs 13.21 mu M). Notably, 83 also displayed potent inhibitory activity (IC50 = 31.73 mu M) against GLUT9. Furthermore, we also preliminarily explored the effect of chirality on the potency of the promising derivatives 44 and 54. Compounds 44, 54, and 83 showed favorable drug-like pharmacokinetics and appear to be promising candidates for the treatment of hyperuricemia and gout.
• Arylazolyl(azinyl)thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors
  作者：Xiao Li、Peng Zhan、Hong Liu、Dongyue Li、Liu Wang、Xuwang Chen、Huiqing Liu、Christophe Pannecouque、Jan Balzarini、Erik De Clercq、Xinyong Liu

  DOI：10.1016/j.bmc.2012.07.026

  日期：2012.9

  In continuation of our efforts toward the discovery of potent HIV-1 NNRTIs with novel structures, we have employed a scaffold hopping strategy to explore the chemically diversed space of bioactive compounds. The original arylazolylthioacetanilide platform was replaced with different imidazopyridinylthioacetanilide scaffolds to yield the optimal pharmacophore moieties in order to generate novel NNRTIs with desirable potency. Some of the new compounds proved able to inhibit HIV-1 replication in the low micromolar range. In particular, compound 5b16 displayed the most potent anti-HIV-1 activity (EC50 = 0.21 +/- 0.06 mu M), inhibiting HIV-1 IIIB replication in MT-4 cells more effectively than dideoxycytidine (EC50 = 1.4 +/- 0.1 mu M) and similarly with nevirapine (EC50 = 0.20 +/- 0.10 mu M). Preliminary structure-activity relationship (SAR) of the newly synthesized congeners is discussed, and molecular modeling study is performed to rationalize the SAR conclusions. (C) 2012 Elsevier Ltd. All rights reserved.